Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

This study has been terminated.
(Difficulty in patient recruitment in the participating sites)
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01389700
First received: July 6, 2011
Last updated: November 25, 2014
Last verified: November 2014

July 6, 2011
November 25, 2014
October 2011
December 2012   (final data collection date for primary outcome measure)
Pharmacokinetics parameters of SAR279356 : Ceoi, AUClast and CL [ Time Frame: 90 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01389700 on ClinicalTrials.gov Archive Site
  • Opsonophagocytic assay (OPA) [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • Opsonophagocytic killing assay (OPK) [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • Dosage of human anti-human antibodies (HAHA) [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • Occurrence of infections [ Time Frame: Up to 28 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation

Primary Objective:

- To determine the pharmacokinetics (PK) of a single intravenous (IV) dose of SAR279356 administered to intensive care unit (ICU) patients on mechanical ventilation

Secondary Objectives:

  • To determine the safety and tolerability of SAR279356
  • To evaluate the pharmacodynamics (PD) and immunogenicity of SAR279356
  • Exploratory efficacy of SAR279356 on prevention of bacterial infections

Total study duration (from screening to last follow-up visit) is 91 days break down as follows:

  • Screening: 1 day prior to dosing;
  • Treatment period: one IV injection on Day 1;
  • Follow-up period: 90 days
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Infection Prophylaxis
  • Drug: SAR279356

    Pharmaceutical form: solution for infusion

    Route of administration: intravenous infusion

  • Drug: placebo

    Pharmaceutical form: solution for infusion

    Route of administration: intravenous infusion

  • Experimental: SAR279356 dose 1
    SAR279356 dose 1, single administration
    Intervention: Drug: SAR279356
  • Experimental: SAR279356 dose 2
    SAR279356 dose 2, single administration
    Intervention: Drug: SAR279356
  • Placebo Comparator: Placebo
    Matching placebo, single administration
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion criteria :

  • ICU patients on mechanical ventilation at the time of randomization
  • Patients or legally authorized representative (LAR) giving written informed consent.

Exclusion criteria:

  • Patients <18 years of age;
  • Documented Pseudomonas infection or colonization in the last 30 days;
  • Immunocompromised patients
  • Hypersensitivity to the study drug and/or to prior therapy with monoclonal antibodies;
  • Patient who has taken other investigational drugs or prohibited therapy for this study within 1 month or 5 half-lives, whichever is longer;
  • Patient or LAR who withdraws consent during the screening (starting from signed informed consent form);
  • Acute liver injury related criteria at the time of study entry:
  • Pregnant or breast-feeding women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01389700
PKD11791, U1111-1118-6717
Not Provided
Not Provided
Not Provided
Sanofi
Sanofi
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP